Publication
Bioengineered extracellular vesicles integrating anti-EphA2 recognition and oxaliplatin delivery for pancreatic cancer therapy.
Shi-Wei Chao, Wan-Chi Tsai, Yung-Han Chang, Shan-Jou Chen, Chia-Tse Li, Jo-Han Fan, Bo-Cheng Huang, Shih-Ting Hong, Hong-Ren Wang, Yu-Ting Huang, Ming-Yii Huang, Chih-Hung Chuang
- Source
- PubMed
- Retrieved
- Sep 29, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-PUBMED-20260929-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
Pancreatic ductal adenocarcinoma (PDAC) remains one of the most lethal solid tumors due to its dense desmoplastic stroma, poor vascular perfusion, and the limited intratumoral delivery of chemotherapeutic agents such as oxaliplatin (OXA). Extracellular vesicles (EVs) offer a biocompatible platform…
Read on PubMedLinked entities
Linked entities (1)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Candidate 1
- cancerMalignant Pancreatic Neoplasmdictionary0.60
Curated evidence
Evidence citing this paper (0)
Data not yet available